Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan

This publication has 25 references indexed in Scilit:

• Editorial: Public Health Nutrition in the Middle East
  Frontiers in Public Health, 2016
• Multi‐country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED)
  Diabetic Medicine, 2015
• Insulin Analogs—Are They Worth It? Yes!
  Diabetes Care, 2014
• Recommendations for Management of Diabetes During Ramadan
  Diabetes Care, 2010
• Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan
  Diabetic Medicine, 2009
• Fasting during the month of ramadan for people with diabetes: Medicine and fiqh united at last
  Ibnosina Journal of Medicine and Biomedical Sciences, 2009
• Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan
  Acta Diabetologica, 2008
• A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting
  Diabetes Research and Clinical Practice, 2007
• A Population-Based Study of Diabetes and Its Characteristics During the Fasting Month of Ramadan in 13 Countries
  Diabetes Care, 2004
• Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan
  Diabetic Medicine, 1999